Grade system. حسب Zhuoyang Xia (21354186)

"…The DerSimonian–Laird random-effects model and the Cochrane Collaboration’s risk of Bias Tool were used for analysis and risk of bias assessment.</p><p>Results</p><p>A total of 12 RCTs involving 18,086 patients were finally included. …"

Literature search. حسب Zhuoyang Xia (21354186)

"…The DerSimonian–Laird random-effects model and the Cochrane Collaboration’s risk of Bias Tool were used for analysis and risk of bias assessment.</p><p>Results</p><p>A total of 12 RCTs involving 18,086 patients were finally included. …"

Study characteristics. حسب Zhuoyang Xia (21354186)

"…The DerSimonian–Laird random-effects model and the Cochrane Collaboration’s risk of Bias Tool were used for analysis and risk of bias assessment.</p><p>Results</p><p>A total of 12 RCTs involving 18,086 patients were finally included. …"

Flowchart of literature retrieval. حسب Zhuoyang Xia (21354186)

"…The DerSimonian–Laird random-effects model and the Cochrane Collaboration’s risk of Bias Tool were used for analysis and risk of bias assessment.</p><p>Results</p><p>A total of 12 RCTs involving 18,086 patients were finally included. …"

Data extraction. حسب Zhuoyang Xia (21354186)

"…The DerSimonian–Laird random-effects model and the Cochrane Collaboration’s risk of Bias Tool were used for analysis and risk of bias assessment.</p><p>Results</p><p>A total of 12 RCTs involving 18,086 patients were finally included. …"

Cochrane Collaboration’s risk of bias tool. حسب Zhuoyang Xia (21354186)

"…The DerSimonian–Laird random-effects model and the Cochrane Collaboration’s risk of Bias Tool were used for analysis and risk of bias assessment.</p><p>Results</p><p>A total of 12 RCTs involving 18,086 patients were finally included. …"

These subfigures show a visualization of the context embeddings for the DSVAE model with LS=2=4,CS=2. The first subfigure from the left shows three patient clusters, the second sub... حسب Eloy Geenjaar (21533195)

Effects of bevacizumab addition on VEGF-A concentrations <i>in vitro</i>. حسب Masashi Okawa (8951294)

Neutralization with additional bevacizumab to serum samples pre- and post-bevacizumab administration. حسب Masashi Okawa (8951294)

"…<b>c</b> Further addition of bevacizumab to serum samples post-bevacizumab administration significantly decreased VEGF-A121 levels in samples to which 20 and 200 μg/mL bevacizumab was added (ANOVA: <i>p</i> < 0.0001; Dunnett’s multiple comparisons test: +2 μg/mL, <i>p</i> = 0.7096 vs control; +20 μg/mL, <i>p</i> = 0.0107 vs control; +200 μg/mL, <i>p</i> < 0.0001 vs control). …"

Blood concentrations of VEGF-A121, VEGF-A165, and VEGF-A pre- and post-bevacizumab administration. حسب Masashi Okawa (8951294)

The original data for the figures. حسب Masashi Okawa (8951294)

Effect of the VEGF-A–bevacizumab complex removal using immunoprecipitation on the concentrations of VEGF-A121, VEGF-A165, and VEGF-A. حسب Masashi Okawa (8951294)

VEGF-A121, VEGF-A165, and VEGF-A contents per unit platelets. حسب Masashi Okawa (8951294)

Equation of the equilibrium dissociation constant of the antigen-antibody reaction. حسب Masashi Okawa (8951294)

Data cleaning and preparation algorithm. حسب Ayana Ablayeva (22103708)

"…</p><p>Conclusions</p><p>Liver cancer morbidity and mortality rates have risen in Kazakhstan over the past decade, with a slight decrease during the early COVID-19 pandemic. …"

The characteristics and clinical features of 12 patients. حسب Masashi Okawa (8951294)

Hypothetical mechanism by which plasma VEGF-A121 concentration is elevated post-bevacizumab administration. حسب Masashi Okawa (8951294)

Effect of adding rhVEGF-A (-121 or -165) on the concentrations of VEGF-A121 and VEGF-A165 in plasma samples. حسب Masashi Okawa (8951294)

Regional and temporal burden of liver cancer in Kazakhstan (2014–2023). حسب Ayana Ablayeva (22103708)

AO/EtBr Staining of Cancer cell lines: <i>To check whether vitamin D3 promoted cell death in cancer cells, a dual staining protocol was implemented as detailed in the methods secti... حسب Vidya G. Bettada (22208808)